Literature DB >> 28450040

Comparison of Predictors of Heart Failure With Preserved Versus Reduced Ejection Fraction in a Multiracial Cohort of Preclinical Left Ventricular Diastolic Dysfunction.

Lili Zhang1, Jared J Liebelt2, Nidhi Madan2, Jian Shan3, Cynthia C Taub4.   

Abstract

Preclinical diastolic dysfunction (PDD) is a well-known but poorly understood risk factor for heart failure. We aimed to investigate risk factors contributing to progression of PDD to heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). Patients with echocardiogram from 2003 to 2008 with left ventricular ejection fraction ≥50%, grade I diastolic dysfunction, and free of clinical heart failure were included. The end point was incident HFpEF or HFrEF. Cumulative probabilities were estimated and multivariable adjusted Cox proportional hazards regressions were performed to examine predictors of incident HFpEF and HFrEF. In total, 7,878 patients with PDD (79.2% nonwhite) were included. At the end of follow-up (median 5.9 years), 146 patients developed HFrEF, and 635 patients developed HFpEF. The 10-year cumulative probabilities of HFrEF and HFpEF were 3.1% and 12.6%, respectively. Incidence of HFrEF was significantly lower in non-Hispanic blacks (2.2%) compared with non-Hispanic whites (4.5%). Age, diabetes, myocardial infarction, and renal disease were independent predictors of both HFrEF and HFpEF. Male gender, cerebrovascular accident, and low baseline left ventricular ejection fraction were associated with HFrEF only; whereas pulmonary disease, blood urea nitrogen, and anemia were predictors of HFpEF only. In conclusion, our results revealed a distinct set of predictors of HFrEF and HFpEF in patients with PDD and underscored a differential approach of risk stratification, prevention, and early treatment based on heart failure subtypes.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28450040     DOI: 10.1016/j.amjcard.2017.03.005

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Sex and Race Differences in Lifetime Risk of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction.

Authors:  Ambarish Pandey; Wally Omar; Colby Ayers; Michael LaMonte; Liviu Klein; Norrina B Allen; Lewis H Kuller; Philip Greenland; Charles B Eaton; John S Gottdiener; Donald M Lloyd-Jones; Jarett D Berry
Journal:  Circulation       Date:  2018-01-19       Impact factor: 29.690

2.  Diastolic function in patients with heart failure with preserved ejection fraction and atrial fibrillation: impact of diabetes.

Authors:  Ruxandra-Nicoleta Horodinschi; Camelia Cristina Diaconu
Journal:  Am J Cardiovasc Dis       Date:  2021-10-25

Review 3.  Effects of Digoxin in Heart Failure (HF) With Reduced Ejection Fraction (EF).

Authors:  Riya R Parikh; Khushbu R Patel; Joseph V Pergolizzi; Frank Breve; Peter Magnusson
Journal:  Cureus       Date:  2022-03-02

4.  Progression of Preclinical Heart Failure: A Description of Stage A and B Heart Failure in a Community Population.

Authors:  Kathleen A Young; Christopher G Scott; Richard J Rodeheffer; Horng H Chen
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2021-05-06

5.  Electrocardiographic characteristics in patients with heart failure and normal ejection fraction: A systematic review and meta-analysis.

Authors:  Theodora Nikolaidou; Nathan A Samuel; Carl Marincowitz; David J Fox; John G F Cleland; Andrew L Clark
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-10-11       Impact factor: 1.468

6.  A risk score for predicting atrial fibrillation in individuals with preclinical diastolic dysfunction: a retrospective study in a single large urban center in the United States.

Authors:  Dan L Li; Renato Quispe; Nidhi Madan; Lili Zhang; Cynthia C Taub
Journal:  BMC Cardiovasc Disord       Date:  2019-02-27       Impact factor: 2.298

Review 7.  Diabetes mellitus and risk of new-onset and recurrent heart failure: a systematic review and meta-analysis.

Authors:  Satoru Kodama; Kazuya Fujihara; Chika Horikawa; Takaaki Sato; Midori Iwanaga; Takaho Yamada; Kiminori Kato; Kenichi Watanabe; Hitoshi Shimano; Tohru Izumi; Hirohito Sone
Journal:  ESC Heart Fail       Date:  2020-07-29

Review 8.  Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects.

Authors:  Giuseppe Palmiero; Arturo Cesaro; Erica Vetrano; Pia Clara Pafundi; Raffaele Galiero; Alfredo Caturano; Elisabetta Moscarella; Felice Gragnano; Teresa Salvatore; Luca Rinaldi; Paolo Calabrò; Ferdinando Carlo Sasso
Journal:  Int J Mol Sci       Date:  2021-05-30       Impact factor: 5.923

Review 9.  Heart Failure with Reduced Ejection Fraction (HFrEF) and Preserved Ejection Fraction (HFpEF): The Diagnostic Value of Circulating MicroRNAs.

Authors:  Yei-Tsung Chen; Lee Lee Wong; Oi Wah Liew; Arthur Mark Richards
Journal:  Cells       Date:  2019-12-16       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.